Pharmacogenomic application of the haptoglobin genotype in the prevention of diabetic cardiovascular disease

Author： Blum Shany   Milman Uzi   Shapira Chen   Levy Andrew P  

Publisher： Future Medicine

ISSN： 1462-2416

Source： Pharmacogenomics, Vol.9, Iss.8, 2008-08, pp. : 989-991

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Vitamin E reduces cardiovascular disease in individuals with diabetes mellitus and the haptoglobin 2-2 genotype

By Blum Shany   Vardi Moshe   Brown Jonathan B   Russell Allen   Milman Uzi   Shapira Chen   Levy Nina S   Miller-Lotan Rachel   Asleh Rabea   Levy Andrew P  

Pharmacogenomics, Vol. 11, Iss. 5, 2010-05 ,pp. : 675-684

Future Medicine

Access to resources Recommend Favorite

The DD-ACE genotype and cardiovascular disease

By Butler R  

Pharmacogenomics, Vol. 1, Iss. 2, 2000-05 ,pp. : 153-167

Future Medicine

Access to resources Recommend Favorite

Pharmaceutical thrombosis prevention in cardiovascular disease

By Eriksson Mats   Christensen Kjeld   Lindahl Tomas L   Larsson Anders  

Expert Opinion on Investigational Drugs, Vol. 11, Iss. 4, 2002-04 ,pp. : 553-563

Informa Healthcare

Access to resources Recommend Favorite

Lipid Management for the Prevention of Cardiovascular Disease

By  

Current Pharmaceutical Design, Vol. 17, Iss. 9, 2011-03 ,pp. : 852-860

Bentham Science Publishers

Access to resources Recommend Favorite

Garlic for Cardiovascular Disease: Prevention or Treatment?

By  

Current Pharmaceutical Design, Vol. 23, Iss. 7, 2017-04 ,pp. : 1028-1041

Bentham Science Publishers

Access to resources Recommend Favorite